Venture capital firm Epidarex Capital raised £47.5m (over $80m) for a UK-based early-stage life science and health tech fund.
Limited partners include King’s College London, Eli Lilly and Co., the European Investment Fund, Scottish Enterprise and Strathclyde Pension Fund.
The fund will lead investments in early-stage life science and health technology companies, including spin-outs from research universities working with the Universities of Edinburgh, Glasgow and Aberdeen, and King’s College London.
Led by Sinclair Dunlop, Managing Partner, Kyp Sirinakis and Liz Roper, Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets working in partnership with the Universities of Edinburgh, Glasgow and Aberdeen.
The firm has offices in Bethesda, Maryland, Edinburgh, UK and Tokyo, Japan.